Market Signal Briefing

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join This Class Action Lawsuit?

Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)?Did you purchase your shares between March 10, 2024, and September 29, 2025, inclusive?Did you lose money in your investment in MoonLake Immunotherapeutics? If you purchased or acquired MoonLake common stock, and/or would like to discuss your legal rights and options please visit MoonLake Immunotherapeutics Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors (the “Class”) who purchased or acquired the common stock of MoonLake between March 10, 2024, and September 29, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

According to the lawsuit, Defendants made misrepresentations concerning the Company’s sole drug candidate, sonelokimab (SLK), which was promoted as superior to competing monoclonal antibody drugs.

If you wish to serve as lead plaintiff for the Class, you must file papers by December 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join This Class Action Lawsuit?

Do you, or did you, own shares of Avantor, Inc. (NYSE: AVTR)?Did you purchase your shares between March 5, 2024, and October 28, 2025, inclusive?Did you lose money in your investment in Avantor, Inc.? If you purchased or acquired Avantor common stock, and/or would like to discuss your legal rights and options please visit Avantor, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

A lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania on behalf of investors (the “Class”) who purchased or acquired the common stock of Avantor between March 5, 2024, and October 28, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

According to the lawsuit, Defendants made misrepresentations concerning the Company’s competitive positioning.

If you wish to serve as lead plaintiff for the Class, you must file papers by December 29, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds V.F. Corporation (“VFC” or the “Company”) (NYSE: VFC) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join This Class Action Lawsuit?

Do you, or did you, own shares of V.F. Corporation (NYSE: VFC)?Did you purchase your shares between October 30, 2023 and May 20, 2025, inclusive?Did you lose money in your investment in V.F. Corporation? If you purchased or acquired VFC securities, and/or would like to discuss your legal rights and options please visit V.F. Corporation Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

A lawsuit was filed in the United States District Court for the District of Colorado on behalf of investors who purchased or acquired the securities of VFC between October 30, 2023 and May 20, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

According to the lawsuit, Defendants made misrepresentations concerning VFC’s business plans.

If you wish to serve as lead plaintiff for the Class, you must file papers by November 12, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join This Class Action Lawsuit?

Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)?Did you purchase your shares between February 26, 2025 and August 5, 2025, inclusive?Did you lose money in your investment in Lantheus Holdings, Inc.? If you purchased or acquired Lantheus securities, and/or would like to discuss your legal rights and options please visit Lantheus Holdings, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired the securities of Lantheus between February 26, 2025 and August 5, 2025, inclusive.

According to the lawsuit, Defendants made misrepresentations concerning the competitive position of the Company’s key Radiopharmaceutical Oncology product, Pylarify.

If you wish to serve as lead plaintiff for the Class, you must file papers by November 10, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

Balanced approach to AI sovereignty needed to ensure Europe’s competitiveness while protecting data

MILAN--(BUSINESS WIRE)--A new study by Accenture (NYSE: ACN) has found that European organizations are placing greater emphasis on maintaining control over data and infrastructure which is likely to accelerate the demand for sovereign AI.

Sovereign AI refers to the ability of a country to develop and deploy AI using local infrastructure, data, models and talent to protect data from foreign access, bolster competitiveness, and decrease reliance on overseas technology providers.

In Europe, 62% of organizations are seeking sovereign solutions in response to current geopolitical uncertainty, a concern that’s heightened among Danish (80%), Irish (72%), and German (72%) organizations. Sectors with regulatory requirements and sensitive data are most likely to lead sovereign AI adoption including banking (76%), public service (69%), and utilities (70%).

This trend is expected to grow over the next two years, as 60% of European organizations plan to increase investments in sovereign AI technology especially those in Germany (73%), Italy (71%) and Switzerland (64%).

Mauro Macchi, Accenture CEO for EMEA commented, "Europe is facing an AI paradox. Its leaders understand the need to accelerate AI adoption to spur innovation and drive growth. But at the same time, because most AI technologies originate from outside the region, it could also be seen as a risk. A sovereign AI approach can help resolve this challenge by enabling European organizations to protect critical operations without hampering innovation and competitiveness. It's with an innovative and thriving economy that we’ll be able to invest in strengthening our technology ecosystem, enabling local champions to grow and compete on the global stage."

Balancing data control and access to global innovation

The survey highlights that, on average, just one-third (36%) of AI initiatives and data within European organizations require a sovereign approach due to regulatory requirements or data sensitivity. Capital markets and public services are sectors where such measures apply to a higher share of data.

European organizations are seeking a balance between data control and access to global innovation, with 65% acknowledging that they cannot remain competitive without non-European technology providers. 57% are considering using sovereign solutions from both European and non-European providers.

For its part, Accenture is helping Telia Cygate gain an early lead helping Swedish organizations adopt scalable and secure AI services. Accenture is also working across the ecosystem in Europe, including with AI infrastructure providers like Amsterdam-based Nebius, to provide clients with a foundation for their own sovereign AI factories that enable them to meet data residency requirements. Nebius is an AI cloud platform engineered to support the full lifecycle of AI workloads, integrating custom hardware, proprietary software and energy-efficient data centers located across Europe and the Middle East.

Mauro Capo, Digital Sovereignty lead for Accenture in EMEA said, "A sovereign AI approach is not about holding everything in one place. The goal is to make technology choices according to the degree of control organizations want to exercise over data, AI infrastructure and models, while benefiting from the scale, service breadth and pace of innovation that some non-European providers offer. These choices are decided by the use case and national priorities. Some cases need only local data residency, while others, in defense for instance, call for full sovereignty over the different AI components - local data, infrastructure and model, advanced encryption, or even air-gapped systems when necessary.”

Reframing sovereignty, from risk management to competitive advantage

Only 19% of organizations view sovereign AI as a competitive advantage, while 48% cite compliance requirements as their primary motivation for adopting sovereign solutions. Sovereign AI is still perceived as a technical issue within businesses, as only 16% of European companies have made AI sovereignty a CEO or board-level concern.

However, there's a growing recognition of its strategic importance, with 73% of organizations calling for governments and institutions, such as the European Union, to play a key role in enhancing Europe's digital sovereignty, through regulations, subsidies, or public investments. Small and medium enterprises are also seen as critical in this pursuit, with 70% of organizations considering it as important to helping them access sovereign solutions.

Accenture recommends four actions to maximize opportunities from sovereign AI:

CEO Ownership: Sovereign AI must be a CEO-led priority, aligning AI strategy with enterprise risk, growth, and geopolitical realities for maximum impact.

Reframe Sovereignty: Organizations should shift from viewing sovereignty as mere risk mitigation to leveraging it as a source of value creation and competitive advantage.

Expand Your Ecosystem: Companies should build hybrid ecosystems that combine local trust with global innovation, tailoring sovereignty measures to where they matter most.

Redefine Architecture: Firms need to architect AI across a multi-cloud continuum, embedding sovereignty into every layer - data, infrastructure, models, and applications - for resilience and adaptability.

About the research

This study combines quantitative, qualitative and policy research to examine how governments and enterprises are advancing sovereign AI and sovereign cloud. It is based on a global survey of 1,928 organizations across 28 countries and 18 industries conducted during Jul–Aug 2025. Respondents were senior technology and policy leaders - CIOs, CTOs, chief data, AI and risk officers - from both public and private sectors.

About Accenture

Accenture is a leading solutions and global professional services company that helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed across the enterprise, bringing together the talent of our approximately 779,000 people, our proprietary assets and platforms, and deep ecosystem relationships. Our strategy is to be the reinvention partner of choice for our clients and to be the most AI-enabled, client-focused, great place to work in the world. Through our Reinvention Services we bring together our capabilities across strategy, consulting, technology, operations, Song and Industry X with our deep industry expertise to create and deliver solutions and services for our clients. Our purpose is to deliver on the promise of technology and human ingenuity, and we measure our success by the 360° value we create for all our stakeholders. Visit us at accenture.com.

Copyright © 2025 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.

Schiphol, November 3, 2025 - Aegon announces today that David Herzog, who was appointed as a member of the Board of Directors (BoD) at Aegon’s 2025 Annual General Meeting of shareholders (AGM), will succeed William Connelly as Chairman of the BoD as of November 13, 2025. In line with previous announcements, Mr Connelly will retire as Chairman and member of the BoD on the same date. 

Aegon also announces today that it will propose to its 2026 AGM to appoint Leni Boeren as a new member of its BoD. Mrs Boeren has extensive experience in both the financial services industry and the wider corporate sector. Her most recent executive role was as CEO of Kempen Capital Management N.V. and as a member of the Executive Board of Van Lanschot Kempen N.V. Prior to this role, Mrs Boeren was CEO and Chair of the Management Board of Robeco Groep N.V., and a member of the Executive Committee at Euronext N.V. Mrs Boeren currently holds non-executive roles at Mollie, NIBC Bank, Ohpen and Air France-KLM. In addition, Mrs Boeren holds several advisory roles, including her membership of the Capital Market Committee of the Dutch Authority for Financial Markets.

William Connelly commented: “I am delighted that the Board will propose Leni Boeren as its new member. Leni has a deep understanding of the financial services and corporate sectors, and extensive experience in transforming companies. She is well placed to contribute to Aegon’s Board and support the execution of the company’s strategy. I am also pleased to pass the chairmanship of the Board to David Herzog, whose wealth of leadership experience in insurance and asset management will be crucial to Aegon's continued success. Looking back on my tenure, it has been a privilege to contribute to Aegon’s transformation, which I am confident will continue under David’s capable leadership.”

David Herzog said: “I look forward to taking on the role of Chairman and working with my fellow Board members to continue advancing Aegon’s strategy and delivering value to our stakeholders. I also look forward to collaborating closely with our CEO, Lard Friese, whose strong leadership has been pivotal in shaping Aegon’s direction. I would like to thank Bill Connelly for his outstanding leadership and dedication to Aegon during his tenure as Chairman. Bill’s vision and commitment have been instrumental in guiding Aegon through its transformation, and I am privileged to build on the strong foundation he has established.”

Contacts

About Aegon

Aegon is an international financial services holding company. Aegon’s ambition is to build leading businesses that offer their customers investment, protection, and retirement solutions. Aegon’s portfolio of businesses includes fully owned businesses in the United States and United Kingdom, and a global asset manager. Aegon also creates value by combining its international expertise with strong local partners via insurance joint-ventures in Spain & Portugal, China, and Brazil, and via asset management partnerships in France and China. In addition, Aegon owns a Bermuda-based life insurer and generates value via a strategic shareholding in a market leading Dutch insurance and pensions company.

Aegon’s purpose of helping people live their best lives runs through all its activities. As a leading global investor and employer, Aegon seeks to have a positive impact by addressing critical environmental and societal issues. Aegon is headquartered in Schiphol, the Netherlands, domiciled in Bermuda, and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com.

Forward-looking statements
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. In addition, any statements that refer to sustainability, environmental and social targets, commitments, goals, efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation, and expressly disclaims any duty, to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:

Changes in general economic and/or governmental conditions, particularly in Bermuda, the United States, the United Kingdom and in relation to Aegon’s shareholding in ASR Nederland N.V. and asset management business, the Netherlands;Civil unrest, (geo-) political tensions, military action or other instability in countries or geographic regions that affect our operations or that affect global markets;Changes in the performance of financial markets, including emerging markets, such as with regard to:          The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;The impact from volatility in credit, equity, and interest rates; Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;The effect of tariffs and potential trade wars on trading markets and on economic growth, globally and in the markets where Aegon operates.Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries;The effect of applicable Bermuda solvency requirements, the European Union’s Solvency II requirements, and applicable equivalent solvency requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain and our ability to pay dividends;Changes in the European Commission’s or European regulator’s position on the equivalence of the supervisory regime for insurance and reinsurance undertakings in force in Bermuda;Changes affecting interest rate levels and low or rapidly changing interest rate levels;Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;The effects of global inflation, or inflation in the markets where Aegon operates;Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;Increasing levels of competition, particularly in the United States, the United Kingdom, emerging markets and in relation to Aegon’s shareholding in ASR Nederland N.V. and asset management business, the Netherlands;Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business;The frequency and severity of insured loss events;Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products and management of derivatives;Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;Customer responsiveness to both new products and distribution channels;Third-party information used by us may prove to be inaccurate and change over time as methodologies and data availability and quality continue to evolve impacting our results and disclosures;As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which Aegon does business, may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;Aegon’s failure to swiftly, effectively, and securely adapt and integrate emerging technologies;The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to complete, or obtain regulatory approval for, acquisitions and divestitures, integrate acquisitions, and realize anticipated results from such transactions, and its ability to separate businesses as part of divestitures. In particular, there is no certainty that Aegon’s review on a potential relocation of the company’s legal domicile and head office to the United States will result in a decision to pursue such a relocation. Furthermore, there is no guarantee, if pursued, what the manner, timing, and potential impacts of a relocation would be and if such relocation can be completed successfully.Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies, as well as other management initiatives related to cost savings, Cash Capital at Holding, gross financial leverage and free cash flow;Changes in the policies of central banks and/or governments;Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;Consequences of an actual or potential break-up of the European Monetary Union in whole or in part, or further consequences of the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;Changes in laws and regulations, or the interpretation thereof by regulators and courts, including as a result of comprehensive reform or shifts away from multilateral approaches to regulation of global or national operations, particularly regarding those laws and regulations related to ESG matters, those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, the attractiveness of certain products to its consumers and Aegon’s intellectual property;Regulatory changes relating to the pensions, investment, insurance industries and enforcing adjustments in the jurisdictions in which Aegon operates;Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national (such as Bermuda) or US federal or state level financial regulation or the application thereof to Aegon;Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels;The rapidly changing landscape for ESG responsibilities, leading to potential challenges by private parties and governmental authorities, and/or changes in ESG standards and requirements, including assumptions, methodology and materiality, or a change by Aegon in applying such standards and requirements, voluntarily or otherwise, may affect Aegon’s ability to meet evolving standards and requirements, or Aegon’s ability to meet its sustainability and ESG-related goals, or related public expectations, which may also negatively affect Aegon’s reputation or the reputation of its board of directors or its management; Unexpected delays, difficulties, and expenses in executing against Aegon’s environmental, climate, or other ESG targets, goals and commitments, and changes in laws or regulations affecting us, such as changes in data privacy, environmental, health and safety laws; andReliance on third-party information in certain of Aegon’s disclosures, which may change over time as methodologies and data availability and quality continue to evolve. These factors, as well as any inaccuracies in third-party information used by Aegon, including in estimates or assumptions, may cause results to differ materially and adversely from statements, estimates, and beliefs made by Aegon or third-parties. Moreover, Aegon’s disclosures based on any standards may change due to revisions in framework requirements, availability of information, changes in its business or applicable governmental policies, or other factors, some of which may be beyond Aegon’s control. Additionally, Aegon's discussion of various ESG and other sustainability issues in this document or in other locations, including on our corporate website, may be informed by the interests of various stakeholders, as well as various ESG standards, frameworks, and regulations (including for the measurement and assessment of underlying data). As such, our disclosures on such issues, including climate-related disclosures, may include information that is not necessarily "material" under US securities laws for SEC reporting purposes, even if we use words such as "material" or "materiality" in relation to those statements. ESG expectations continue to evolve, often quickly, including for matters outside of our control; our disclosures are inherently dependent on the methodology (including any related assumptions or estimates) and data used, and there can be no guarantee that such disclosures will necessarily reflect or be consistent with the preferred practices or interpretations of particular stakeholders, either currently or in future. This document contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the 2024 Integrated Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

20251103_PR_Aegon announces changes to its Board of Directors

DALLAS--(BUSINESS WIRE)--Kosmos Energy Ltd. (“Kosmos” or the “Company”) (NYSE/LSE: KOS) announced today its financial and operating results for the third quarter of 2025. For the quarter, the Company generated a net loss of $124 million, or $0.26 per diluted share. When adjusted for certain items that impact the comparability of results, the Company generated an adjusted net loss(1) of $72 million, or $0.15 per diluted share for the third quarter of 2025.

THIRD QUARTER 2025 HIGHLIGHTS

Net Production(2): ~65,500 barrels of oil equivalent per day (boepd), up 3% versus second quarter 2025, with sales of ~59,900 boepd

Revenues: $311 million, or $56.39 per boe (excluding the impact of derivative cash settlements)

Production expense: $148 million ($19.51 per boe excluding $59.4 million of production expenses associated with the Greater Tortue Ahmeyim (GTA) liquefied natural gas (LNG) project), down 39% versus second quarter 2025

Capital expenditures: $67 million

Entered into a senior secured term loan with Shell for up to $250 million; funding of the first tranche of $150 million was completed post quarter-end with proceeds used to partially redeem the 2026 unsecured notes

Completed the semi-annual re-determination of the reserve-based lending (“RBL”) facility, maintaining a borrowing base in excess of the RBL’s $1.35 billion facility size

During the third quarter, 6.8 gross LNG cargos were lifted from the GTA project offshore Mauritania and Senegal

First producer well of the 2025/26 Jubilee drilling campaign brought online with ~10,000 bopd average contribution

Commenting on the Company’s third quarter 2025 performance, Chairman and Chief Executive Officer Andrew G. Inglis said: "We set out this year with three clear priorities: Increase production, reduce costs and enhance the resilience of the balance sheet. During the period, we have continued to make good progress against each of these priorities.

On production, GTA is fully operational, with ~7 gross LNG cargos lifted during the quarter, and further upside to be tested in the fourth quarter. With the second Jubilee producer well now being drilled and due online around year end, and the drilling program continuing into 2026, we expect company production to continue to rise through next year.

On costs, we now expect capital expenditure to be below $350 million in 2025, more than 60% lower year-on-year. Operating costs across every business were lower quarter over quarter and we continue to work to further reduce operating costs across the portfolio, particularly on GTA into 2026. In addition, we remain on track to deliver the targeted $25 million of overhead reduction by year-end.

On the balance sheet, we raised additional liquidity with the Shell term loan, which is being used to repay our 2026 maturities. We also completed the semi-annual re-determination of our RBL facility and have added more hedges for 2026.

As we navigate through near-term volatility, our priorities for Kosmos remain consistent: long term value creation through growing production, reducing costs and maximizing cash flow to accelerate debt repayment and reduce leverage.”

FINANCIAL UPDATE

Kosmos entered into a senior secured term loan facility (the “Term Facility”) with Shell Trading (US) Company (“Shell”) for up to $250 million, using $150 million to partially redeem the outstanding 2026 unsecured notes in early October. The remaining $100 million of outstanding 2026 notes is planned to be repaid in advance of the maturity date from the undrawn portion of the Term Facility in the first quarter of 2026. The Company also continues to evaluate raising additional secured debt capital to proactively manage upcoming maturities.

During the third quarter, Kosmos completed the semi-annual re-determination of its RBL facility with a borrowing base in excess of the $1.35 billion facility size. In addition, the Company completed the liquidity test covering the 2027 unsecured notes, which was carried out alongside the RBL re-determination.

Kosmos has continued to add more hedges as part of a rolling hedging program to provide downside protection against a volatile commodity price backdrop. The company now has 2.5 million barrels of remaining 2025 oil production hedged with an average floor of approximately $62/barrel. Kosmos took advantage of periods of higher oil prices during the third quarter to add more hedges for the 2026 hedging program. Kosmos now has 8.5 million barrels of oil hedged for 2026 with an average floor of $66/barrel, weighted towards the first half of the year and is targeting around 50% of 2026 oil production to be hedged by year-end.

Net capital expenditure for the third quarter of 2025 was $67 million, below guidance due to lower spend in Ghana and the Gulf of America. We now expect full year capital expenditures to be lower than $350 million. The Company remains on track to deliver the targeted $25 million overhead reduction by year-end.

The Company generated net cash used in operating activities of approximately $(28) million and free cash flow(1) of approximately $(99) million during the quarter. Excluding the working capital draw communicated with the second quarter results in August, which largely related to final accrued capital expenditure on Phase 1 of the GTA project, free cash flow was broadly neutral for the third quarter.

Kosmos exited the third quarter of 2025 with approximately $2.9 billion of net debt(1) and liquidity of approximately $540 million(3).

OPERATIONAL UPDATE

Production

Total net production(2) in the third quarter of 2025 averaged approximately 65,500 boepd with the quarter-on-quarter increase largely driven by the ramp up at GTA and increased production at Jubilee.

The Company exited the quarter in a net underlift position of approximately 0.6 mmboe.

Mauritania and Senegal

GTA Phase 1 production continued to ramp up during the quarter averaging approximately 11,400 boepd net. During the quarter, 6.8 gross LNG cargos were lifted, in line with guidance. Post quarter-end, an additional 2.7 gross LNG cargos were lifted (bringing the total through October to 13.5), along with the first gross condensate cargo.

Lowering operating costs for GTA Phase 1 remains a priority for the partnership. Net operating costs on the project decreased approximately $10 million quarter-on-quarter, with additional actions to further reduce costs ongoing, including the FPSO lease re-financing which is targeted for completion by year-end, and the implementation of a lower-cost operating model.

During the third quarter, planned startup maintenance was carried out on three of the four FLNG trains. All three trains are back online and the fourth train is scheduled to undergo one week of similar maintenance in the fourth quarter.

With Phase 1 targeting nameplate production at the end of the fourth quarter, the partnership is now focusing on future expansion through Phase 1+, a low-cost brownfield expansion. This is expected to approximately double gas throughput by 2029, leveraging the existing infrastructure in place.

Ghana

Production in Ghana averaged approximately 31,300 boepd net in the third quarter of 2025. Kosmos lifted 2 cargos from Ghana during the quarter, as expected.

At Jubilee (38.6% working interest), oil production in the third quarter averaged approximately 62,500 bopd gross.

The first producer well of the 2025/26 Jubilee drilling campaign came online in July and initial production levels have been encouraging, averaging ~10,000 boepd through the first three months. Following a period of scheduled maintenance, the Noble Venturer rig arrived back in field in mid-October and has spud the second planned producer well, which is expected online around year end. Within the original 2026 drilling campaign budget, the joint venture partners have approved the activity set, which now includes the 4 planned producers and an additional water injector.

In the third quarter of 2025, Ghana gas production net to Kosmos was approximately 5,200 boepd, lower than planned as a result of extended scheduled maintenance on the onshore gas processing plant.

At TEN (20.4% working interest), oil production averaged approximately 16,100 bopd gross for the third quarter. The TEN partnership is finalizing a sale and purchase agreement to acquire the TEN FPSO at the end of its current lease, planned to be signed by year-end. We expect this to significantly reduce TEN operating costs and positively impact our leverage in 2025 and beyond.

Post the signing of the Memorandum of Understanding (MoU) with the Government of Ghana last quarter, all documentation for the extension of the production licenses to 2040 have been prepared for submission to the government for final approval. Once approved, Kosmos expects to recognize a material uplift in its 2P reserve base.

Gulf of America

Production in the Gulf of America averaged approximately 16,600 boepd net (~84% oil) during the third quarter, in line with guidance helped by strong performance from Odd Job and Kodiak and no storm downtime, offset by some unplanned facility downtime and the Winterfell-4 well. The Winterfell-4 well was abandoned in September by the operator due to challenges encountered during completion operations arising from the collapse of the production casing. As a result, all associated drilling and completion costs of approximately $51.1 million related to Winterfell-4 have been written off in the third quarter of 2025. The partnership is reviewing alternative options to access the reserves targeted by Winterfell-4. In 2026, our focus will be on restoring production from the Winterfell-3 fault block.

On Tiberius, Kosmos (operator, 50% working interest) continues to progress the development plan with our partner Oxy (50% working interest). A production handling agreement for the Oxy-operated Lucius platform was executed in the third quarter. Final investment decision and a farm down to reduce Kosmos’ working interest is expected in 2026.

On Gettysburg, a discovered resource opportunity acquired in a previous lease sale, Kosmos (25% working interest) has partnered with Shell (operator, 75% working interest), to plan and progress a low-cost, single well tie-back development to Shell’s operated-Appomattox facility.

Equatorial Guinea

Production in Equatorial Guinea averaged approximately 17,700 bopd gross and 6,200 bopd net in the third quarter. Kosmos lifted 0.7 cargos from Equatorial Guinea during the quarter in line with guidance. As previously communicated, third quarter production was impacted by subsea pump mechanical failures at Ceiba. The first pump was repaired ahead of schedule early in the fourth quarter, and the second pump is now also expected online in the fourth quarter followed by the third pump in first quarter of 2026.

(1) A Non-GAAP measure, see attached reconciliation of non-GAAP measure.

(2) Production means net entitlement volumes. In Ghana, Equatorial Guinea, and Mauritania and Senegal this means those volumes net to Kosmos' working interest or participating interest and net of royalty or production sharing contract effect. In the Gulf of America, this means those volumes net to Kosmos' working interest and net of royalty.

(3) At September 30, 2025, we had liquidity of approximately $540 million consisting of approximately $64 million in cash and cash equivalents, undrawn availability under the Facility of $225 million and undrawn availability under the Term Facility of $250 million. Under the terms of the Credit Agreement, borrowings on the Term Facility are required to be utilized to pay down the 7.125% Senior Notes due 2026 unless otherwise previously repaid.

Conference Call and Webcast Information

Kosmos will host a conference call and webcast to discuss third quarter 2025 financial and operating results today, November 3, 2025, at 10:00 a.m. Central time (11:00 a.m. Eastern time). The live webcast of the event can be accessed on the Investors page of Kosmos’ website at http://investors.kosmosenergy.com/investor-events. The dial-in telephone number for the call is +1-877-407-0784. Callers in the United Kingdom should call 0800 756 3429. Callers outside the United States should dial +1-201-689-8560. A replay of the webcast will be available on the Investors page of Kosmos’ website for approximately 90 days following the event.

About Kosmos Energy

Kosmos Energy is a leading deepwater exploration and production company focused on meeting the world’s growing demand for energy. We have diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. Additionally, in the proven basins where we operate we are advancing high-quality development opportunities, which have come from our exploration success. Kosmos is listed on the NYSE and LSE and is traded under the ticker symbol KOS. As an ethical and transparent company, Kosmos is committed to doing things the right way. The Company’s Business Principles articulate our commitment to transparency, ethics, human rights, safety and the environment. Read more about this commitment in the Kosmos Sustainability Report. For additional information, visit www.kosmosenergy.com.

Non-GAAP Financial Measures

EBITDAX, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, and net debt are supplemental non-GAAP financial measures used by management and external users of the Company's consolidated financial statements, such as industry analysts, investors, lenders and rating agencies. The Company defines EBITDAX as Net income (loss) plus (i) exploration expense, (ii) depletion, depreciation and amortization expense, (iii) equity based compensation expense, (iv) unrealized (gain) loss on commodity derivatives (realized losses are deducted and realized gains are added back), (v) (gain) loss on sale of oil and gas properties, (vi) interest (income) expense, (vii) income taxes, (viii) debt modifications and extinguishments, (ix) doubtful accounts expense and (x) similar other material items which management believes affect the comparability of operating results. The Company defines Adjusted net income (loss) as Net income (loss) adjusted for certain items that impact the comparability of results. The Company defines free cash flow as net cash provided by operating activities less Oil and gas assets, Other property, and certain other items that may affect the comparability of results and excludes non-recurring activity such as acquisitions, divestitures and National Oil Company ("NOC") financing. NOC financing refers to the amounts funded by Kosmos under the Carry Advance Agreements that the Company has in place with the national oil companies of each of Mauritania and Senegal related to the financing of the respective national oil companies’ share of certain development costs at Greater Tortue Ahmeyim. The Company defines net debt as total long-term debt less cash and cash equivalents and total restricted cash.

We believe that EBITDAX, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, Net debt and other similar measures are useful to investors because they are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in the oil and gas sector and will provide investors with a useful tool for assessing the comparability between periods, among securities analysts, as well as company by company. EBITDAX, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, and net debt as presented by us may not be comparable to similarly titled measures of other companies.

This release also contains certain forward-looking non-GAAP financial measures, including free cash flow. Due to the forward-looking nature of the aforementioned non-GAAP financial measures, management cannot reliably or reasonably predict certain of the necessary components of the most directly comparable forward-looking GAAP measures, such as future impairments and future changes in working capital. Accordingly, we are unable to present a quantitative reconciliation of such forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures. Amounts excluded from these non-GAAP measures in future periods could be significant.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Kosmos expects, believes or anticipates will or may occur in the future are forward-looking statements. Kosmos’ estimates and forward-looking statements are mainly based on its current expectations and estimates of future events and trends, which affect or may affect its businesses and operations. Although Kosmos believes that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made in light of information currently available to Kosmos. When used in this press release, the words “anticipate,” “believe,” “intend,” “expect,” “plan,” “will” or other similar words are intended to identify forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Kosmos, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on such assumptions, risks and uncertainties is available in Kosmos’ Securities and Exchange Commission (“SEC”) filings. Kosmos undertakes no obligation and does not intend to update or correct these forward-looking statements to reflect events or circumstances occurring after the date of this press release, except as required by applicable law. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

 

Kosmos Energy Ltd.

Consolidated Statements of Operations

(In thousands, except per share amounts, unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Revenues and other income:

Oil and gas revenue

$

310,959

$

407,794

$

993,729

$

1,277,797

Gain on sale of assets

—

—

600

—

Other income, net

270

37

849

109

Total revenues and other income

311,229

407,831

995,178

1,277,906

Costs and expenses:

Oil and gas production

147,696

133,471

558,122

377,822

Exploration expenses

54,948

14,697

68,686

39,992

General and administrative

12,886

23,298

58,215

76,724

Depletion, depreciation and amortization

141,514

120,728

413,449

311,750

Interest and other financing costs, net

57,919

22,112

164,595

75,839

Derivatives, net

(3,646

)

(15,254

)

(18,480

)

5,716

Other expenses, net

6,384

2,227

14,854

6,418

Total costs and expenses

417,701

301,279

1,259,441

894,261

Income (loss) before income taxes

(106,472

)

106,552

(264,263

)

383,645

Income tax expense

17,827

61,578

58,382

187,215

Net income (loss)

$

(124,299

)

$

44,974

$

(322,645

)

$

196,430

Net income (loss) per share:

Basic

$

(0.26

)

$

0.10

$

(0.68

)

$

0.42

Diluted

$

(0.26

)

$

0.09

$

(0.68

)

$

0.41

Weighted average number of shares used to compute net income (loss) per share:

Basic

478,254

471,816

477,344

470,491

Diluted

478,254

479,190

477,344

478,701

Kosmos Energy Ltd.

Condensed Consolidated Balance Sheets

(In thousands, unaudited)

September 30,

December 31,

2025

2024

Assets

Current assets:

Cash and cash equivalents

$

64,032

$

84,972

Receivables, net

103,330

164,959

Other current assets

198,205

196,201

Total current assets

365,567

446,132

Property and equipment, net

4,208,535

4,444,221

Other non-current assets

515,639

418,635

Total assets

$

5,089,741

$

5,308,988

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

200,809

$

349,994

Accrued liabilities

251,310

244,954

Current maturities of long-term debt

250,000

—

Other current liabilities

3,239

—

Total current liabilities

705,358

594,948

Long-term liabilities:

Long-term debt, net

2,728,500

2,744,712

Deferred tax liabilities

313,426

313,433

Other non-current liabilities

443,670

455,471

Total long-term liabilities

3,485,596

3,513,616

Total stockholders’ equity

898,787

1,200,424

Total liabilities and stockholders’ equity

$

5,089,741

$

5,308,988

Kosmos Energy Ltd.

Condensed Consolidated Statements of Cash Flow

(In thousands, unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Operating activities:

Net income (loss)

$

(124,299

)

$

44,974

$

(322,645

)

$

196,430

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depletion, depreciation and amortization (including deferred financing costs)

143,403

122,887

419,111

318,564

Deferred income taxes

(950

)

6,081

686

11,280

Unsuccessful well costs and leasehold impairments

51,211

1,187

51,373

3,872

Change in fair value of derivatives

(2,792

)

(9,298

)

(10,675

)

11,808

Cash settlements on derivatives, net(1)

(3,480

)

(7,388

)

2,801

(14,754

)

Equity-based compensation

5,302

10,034

21,009

27,849

Gain on sale of assets

—

—

(600

)

—

Debt modifications and extinguishments

—

2,263

—

24,794

Other

(2,986

)

(138

)

(11,492

)

(12,126

)

Changes in assets and liabilities:

Net changes in working capital

(92,977

)

(164,320

)

(50,856

)

(65,215

)

Net cash provided by (used in) operating activities

(27,568

)

6,282

98,712

502,502

Investing activities

Oil and gas assets

(71,367

)

(219,245

)

(244,133

)

(772,238

)

Notes receivable and other investing activities

—

—

(86,791

)

(2,575

)

Net cash used in investing activities

(71,367

)

(219,245

)

(330,924

)

(774,813

)

Financing activities:

Borrowings under long-term debt

175,000

100,000

375,000

275,000

Payments on long-term debt

(50,000

)

—

(150,000

)

(350,000

)

Net proceeds from issuance of senior notes

—

494,855

—

885,285

Purchase of capped call transactions

—

—

—

(49,800

)

Repurchase of senior notes

—

(499,515

)

—

(499,515

)

Other financing costs

—

(4,609

)

(1

)

(35,534

)

Net cash provided by financing activities

125,000

90,731

224,999

225,436

Net increase (decrease) in cash, cash equivalents and restricted cash

26,065

(122,232

)

(7,213

)

(46,875

)

Cash, cash equivalents and restricted cash at beginning of period

51,999

174,118

85,277

98,761

Cash, cash equivalents and restricted cash at end of period

$

78,064

$

51,886

$

78,064

$

51,886

Kosmos Energy Ltd.

EBITDAX

(In thousands, unaudited)

Three Months Ended

Nine months ended

Twelve Months

Ended

September 30,

2025

September 30,

2024

September 30,

2025

September 30,

2024

September 30,

2025

Net income (loss)

$

(124,299

)

$

44,974

$

(322,645

)

$

196,430

$

(329,224

)

Exploration expenses

54,948

14,697

68,686

39,992

148,601

Depletion, depreciation and amortization

141,514

120,728

413,449

311,750

558,473

Equity-based compensation

5,302

10,034

21,009

27,849

31,111

Derivatives, net

(3,646

)

(15,254

)

(18,480

)

5,716

(12,097

)

Cash settlements on commodity derivatives

(2,324

)

(2,532

)

7,340

(9,956

)

4,808

Other expenses, net(1)

6,384

2,227

14,854

6,418

26,139

Gain on sale of assets

—

—

(600

)

—

(600

)

Interest and other financing costs, net

57,919

22,112

164,595

75,839

177,354

Income tax expense

17,827

61,578

58,382

187,215

31,128

EBITDAX

$

153,625

$

258,564

$

406,590

$

841,253

$

635,693

EBITDAX - M/S

(21,988

)

(42,986

)

(131,397

)

(66,418

)

(169,336

)

EBITDAX - Base Business

$

175,613

$

301,550

$

537,987

$

907,671

$

805,029

September 30,

December 31,

2025

2024

Total long-term debt

$

3,025,274

$

2,800,274

Cash and cash equivalents

64,032

84,972

Total restricted cash

14,032

305

Net debt

$

2,947,210

$

2,714,997

 

Kosmos Energy Ltd.

Adjusted Net Income (Loss)

(In thousands, except per share amounts, unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Net income (loss)

$

(124,299

)

$

44,974

$

(322,645

)

$

196,430

Derivatives, net

(3,646

)

(15,254

)

(18,480

)

5,716

Cash settlements on commodity derivatives

(2,324

)

(2,532

)

7,340

(9,956

)

Gain on sale of assets

—

—

(600

)

—

Other, net(2)

6,358

1,965

14,386

5,892

Impairment of suspended well costs

51,060

—

51,060

—

Debt modifications and extinguishments

—

2,263

—

24,794

Total selected items before tax

51,448

(13,558

)

53,706

26,446

Income tax (expense) benefit on adjustments(1)

575

6,186

(1,459

)

2,269

Impact of valuation adjustments and other tax items

—

—

—

(7,963

)

Adjusted net income (loss)

$

(72,276

)

37,602

(270,398

)

217,182

Net income (loss) per diluted share

$

(0.26

)

$

0.09

$

(0.68

)

$

0.41

Derivatives, net

(0.01

)

(0.03

)

(0.04

)

0.01

Cash settlements on commodity derivatives

—

—

0.02

(0.01

)

Other, net(2)

0.01

—

0.03

0.01

Impairment of suspended well costs

0.11

—

0.10

—

Debt modifications and extinguishments

—

—

—

0.05

Total selected items before tax

0.11

(0.03

)

0.11

0.06

Income tax (expense) benefit on adjustments(1)

—

0.02

—

Impact of valuation adjustments and other tax items

—

—

—

(0.02

)

Adjusted net income (loss) per diluted share

$

(0.15

)

$

0.08

$

(0.57

)

$

0.45

Weighted average number of diluted shares

478,254

479,190

477,344

478,701

Kosmos Energy Ltd.

Free Cash Flow

(In thousands, unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Reconciliation of free cash flow:

Net cash provided by (used in) operating activities

$

(27,568

)

$

6,282

$

98,712

$

502,502

Net cash used for oil and gas assets

(71,367

)

(219,245

)

(244,133

)

(772,238

)

Free cash flow

(98,935

)

(212,963

)

(145,421

)

(269,736

)

Net cash provided by (used in) operating activities - M/S

(97,195

)

(56,484

)

(200,456

)

42,542

Net cash used for oil and gas assets - M/S

$

(7,744

)

$

(110,804

)

$

(71,321

)

$

(388,412

)

Base business free cash flow

$

6,004

$

(45,675

)

$

126,356

$

76,134

 

Kosmos Energy Ltd.

Operational Summary

(In thousands, except barrel and per barrel data, unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2025

2024

2025

2024

Net Volume Sold

 

Oil (MMBbl)

3.799

5.135

12.822

 

15.234

Gas (MMcf)

9.712

(1)

3.554

(2)

21.004

 

(1)

11.991

(2)

NGL (MMBbl)

0.097

0.084

0.301

 

0.232

Total (MMBoe)

5.515

5.811

16.624

 

17.465

Total (Mboepd)

59.942

63.167

60.893

 

63.739

 

Revenue

 

Oil sales

$

255,661

$

393,555

$

880,584

 

$

1,230,772

Gas sales

53,761

12,586

107,439

 

42,218

NGL sales

1,537

1,653

5,706

 

4,807

Total oil and gas revenue

310,959

407,794

993,729

 

1,277,797

Cash settlements on commodity derivatives

(2,324

)

(2,532

)

7,340

 

(9,956

)

Realized revenue

$

308,635

$

405,262

$

1,001,069

 

$

1,267,841

 

 

Oil and Gas Production Costs

$

147,696

(1)

$

133,471

(2)

$

558,122

 

(1)

$

377,822

(2)

 

Sales per Bbl/Mcf/Boe

 

Average oil sales price per Bbl

$

67.30

$

76.64

$

68.68

 

$

80.79

Average gas sales price per Mcf

5.54

3.54

5.12

 

3.52

Average NGL sales price per Bbl

15.85

19.68

18.96

 

20.72

Average total sales price per Boe

56.39

70.18

59.78

 

73.16

Cash settlements on commodity derivatives per Boe

(0.42

)

(0.44

)

0.44

 

(0.57

)

Realized revenue per Boe

55.97

69.74

60.22

 

72.59

 

Oil and gas production costs per Boe

$

26.78

$

22.97

$

33.57

 

$

21.64

Oil and gas production costs per Boe ex. M/S (1)(2)

$

19.51

$

16.14

$

24.67

 

$

18.32

_____________________________________

(1)

Includes $59.4 million and $186.6 million for the three and nine months ended September 30, 2025, respectively, of oil and gas production costs related to the LNG production at the GTA Phase 1 project in Mauritania and Senegal. GTA Phase 1 project LNG sales volumes for the three and nine months ended September 30, 2025 were 5.932 MMcf and 9.376 MMcf, respectively. Oil and gas production costs per Boe excluding the GTA Phase 1 LNG project in Mauritania and Senegal for the three and nine months ended September 30, 2025, was $19.51 and $24.67, respectively. First LNG was achieved in February 2025 and the first LNG cargo was successfully completed in April 2025.

(2)

Includes $39.7 million and $57.9 million for the three and nine months ended September 30, 2024, respectively, of oil and gas production costs related to the LNG production at the GTA Phase 1 project in Mauritania and Senegal. First LNG was achieved in February 2025 and the first LNG cargo was successfully completed in April 2025. Oil and gas production costs per Boe excluding the GTA Phase 1 LNG project in Mauritania and Senegal for the three and nine months ended September 30, 2024, was $16.14 and $18.32, respectively.

Kosmos was underlifted by approximately 0.6 million barrels of oil equivalent (mmboe) as of September 30, 2025.

Kosmos Energy Ltd.

Hedging Summary

As of September 30, 2025(1)

(Unaudited)

Weighted Average Price per Bbl

Index

MBbl

Floor(2)

Sold Put

Ceiling

2025:

Two-way collars

Dated Brent

2,000

$

60.00

—

$

74.94

Three-way collars

Dated Brent

500

70.00

55.00

85.00

2026:

Two-way collars 1H26

Dated Brent

1,000

$

60.00

—

$

74.75

Three-way collars FY26

Dated Brent

2,000

60.00

50.00

75.51

Swaps 1H26

Dated Brent

1,000

72.90

—

—

Swaps FY26

Dated Brent

3,000

70.62

—

—

Swaps FY26

WTI

1,500

64.83

—

—

_____________________________________

(1)

Please see the Company’s filed 10-Q for additional disclosure on hedging material. Includes hedging position as of September 30, 2025 and hedges put in place through filing date.

(2)

“Floor” represents floor price for collars and strike price for purchased puts.

Note: Excludes 2.0 MMBbls of Dated Brent sold calls with a strike price of $80.00 per Bbl and 2.0 MMBbls of Dated Brent sold puts with a strike price of $55.00 in 2026. Excludes 1.5 MMBbls of WTI sold puts with a strike price of $50.00 in 2026.

2025 Guidance

4Q 2025

FY 2025 Guidance

Production(1,2,3)

66,000 - 72,000 boe per day

~65,000 boe per day

Opex(4)

$15.00 - $18.00 per boe

~$22.00 per boe

DD&A

$21.00 - $23.00 per boe

$22.00 - $24.00 per boe

G&A(~66% cash)

~$15 million

~$75 million

Exploration Expense(5)

~$10 million

$25 - $45 million

Net Interest Expense(6)

$55 - $60 million

~$220 million

Tax

$4.00 - $6.00 per boe

$4.00 - $6.00 per boe

Capital Expenditure

$80 - $100 million

<$350 million

_____________________________________

Note: Ghana / Equatorial Guinea / Mauritania & Senegal revenue calculated by number of cargos.

(1)

4Q 2025 net cargo forecast – Ghana: 2-3 cargos / Equatorial Guinea: 0.5 cargo. FY 2025 Ghana: 9-10 cargos / Equatorial Guinea 2.7 cargos. Average cargo sizes 950,000 barrels of oil.

(2)

4Q 2025 gross cargo forecast - Mauritania & Senegal: 7-8.5 cargos. FY 2025: 18-19 cargos. Average cargo size ~170,000 m3 with Kosmos NRI of ~24%.

(3)

Gulf of America Production: 4Q 2025 forecast 17,000 - 19,000 boe per day. FY 2025: 17,000-19,000 boe per day. Oil/Gas/NGL split for 2025: ~83%/~11%/~6%.

(4)

FY 2025 opex excludes operating costs associated with GTA, which are expected to total approximately $225 - $245 million net ($45 - $55 million in 4Q 2025). These values include cost associated with the FPSO lease which total approximately $60 million FY 2025 and $15 million 4Q 2025.

(5)

Excludes leasehold impairments and dry hole costs

(6)

Includes capitalized interest

More News From Kosmos Energy Ltd.

By Reuters

November 3, 20257:06 AM UTCUpdated ago

Item 1 of 2 The logo of Italian energy company Eni is seen at a gas station in Rome, Italy September 30, 2018. REUTERS/Alessandro Bianchi

[1/2]The logo of Italian energy company Eni is seen at a gas station in Rome, Italy September 30, 2018. REUTERS/Alessandro Bianchi Purchase Licensing Rights, opens new tab

CompaniesDUBAI, Nov 3 (Reuters) - Italy's Eni and Malaysia's state energy firm Petronas said on Monday they had signed a binding agreement to form a jointly owned company combining their upstream oil and gas assets in Indonesia and Malaysia.

The new entity, NewCo, will manage 19 assets, 14 in Indonesia and five in Malaysia, with plans to invest over $15 billion in the next five years to develop about 3 billion barrels of discovered reserves and explore a further 10 billion barrels.

Sign up here.

The agreement was signed at ADIPEC in Abu Dhabi.

Reporting by Yousef Saba; Writing by Tala Ramadan; Editing by Kim Coghill

Our Standards: The Thomson Reuters Trust Principles., opens new tab

By Reuters

November 3, 20257:16 AM UTCUpdated ago

The BP logo is seen at a BP gas station in Manhattan, New York City, U.S., November 24, 2021. REUTERS/Andrew Kelly Purchase Licensing Rights, opens new tab

CompaniesNov 3 (Reuters) - BP

(BP.L), opens new tab said on Monday it would sell stakes in the Permian and Eagle Ford midstream assets of its U.S. onshore oil and gas business for $1.5 billion to funds managed by investment firm Sixth Street.

The sale comes as BP reviews how to develop its oil and gas production assets and cut costs as part of a $20 billion divestment programme by end-2027.

Sign up here.

It has been under pressure from investors after years of underperforming rivals and also the target of activist investor Elliott.

BP's U.S. onshore oil and gas business, bpx energy, will hold a 51% stake in the Permian assets and 25% in the Eagle Ford assets after the deal, the oil major said.

Reporting by Shashwat Awasthi in Bengaluru; Editing by Subhranshu Sahu

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Tronox Holdings plc ("Tronox" or "the Company") (NYSE: TROX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of TROX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  February 12, 2025 to July 30, 2025

DEADLINE: November 3, 2025

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Tronox suffered from declining sales and increased costs despite its overly optimistic sales projections. Based on these facts, Tronox's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against V.F. Corporation ("VF" or "the Company") (NYSE: VFC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 30, 2023 and May 20, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. VF promised investors its revenue outlook was reliable and minimized the risk of seasonality and macroeconomic fluctuations. The Company's positivity on growth as well as cost-cutting measures had no basis in reality. Based on these facts, the Company's public statements were false and materially misleading. When the market learned the truth about VF, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

Nvidia stock has surged 1,400% over the last three years. While shares have gained significantly, the company still has several catalysts on the horizon.

SummaryThe forward 4-quarter estimate this week jumped to $294.87 from last week's $294.81 and August 1st’s $281.15.The S&P 500 has seen positive revisions in the 2027 EPS estimate since August 1, ’25.If the S&P 500 benchmark just meets that EPS growth target in ’26 and returns 14%, it will be the fourth year in a row of mid-teens or better returns for the benchmark, with ’23 and ’24 returns being 25% each.Higher S&P 500 estimates from positive revisions, gradually declining short-term interest rates from an easier Fed, and a pro-business Administration in Washington all represent tailwinds for solid market returns. ArtistGNDphotography/E+ via Getty Images

It’s hard to be bearish when investors are seeing S&P 500 calendar year EPS estimates get revised like this:

(Source: LSEG)

Note the positive revisions in the 2027 EPS estimate since August 1, ’25.

Someone

Recommended For You

By Reuters

November 3, 20255:55 AM UTCUpdated ago

Darren Woods, CEO of ExxonMobil, speaks at the Asia-Pacific Economic Cooperation (APEC) CEO Summit in San Francisco, California, U.S., November 15, 2023. REUTERS/Carlos Barria Purchase Licensing Rights, opens new tab

CompaniesABU DHABI, Nov 3 (Reuters) - ExxonMobil CEO Darren Woods told Reuters on Monday it will be impossible for the energy giant to continue doing business in Europe if the European Union doesn't make significant changes to a sustainability law that threatens to penalize companies with fines of 5% of global revenue.

Woods said EU lawmakers are listening to opposition to the law, but he has not seen significant changes to it yet.

Sign up here.

Reporting by Andrew Mills; Editing by Tom Hogue

Our Standards: The Thomson Reuters Trust Principles., opens new tab

– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion –

– Gazyva has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwide –

– If approved, Gazyva would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity –

– These positive results follow the recent U.S. FDA approval and positive EU CHMP opinion for Gazyva in lupus nephritis, alongside positive Phase III data from the INShore study in idiopathic nephrotic syndrome –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the Phase III ALLEGORY study of Gazyva® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva versus standard therapy. SRI is a tool that assesses changes in disease severity, symptoms and physical condition to indicate whether treatment is effective at controlling disease activity. All key secondary endpoints were also met. No new safety signals were identified, and safety was in line with the well-characterized profile of Gazyva.

“Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are unprecedented in demonstrating that by effectively controlling disease activity, Gazyva may delay or prevent further organ damage in people with SLE,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We look forward to sharing the data with global health authorities, with the goal of making this potentially transformative new standard of care available as quickly as possible.”

All key secondary endpoints were met, with results showing statistically significant and clinically meaningful benefits with Gazyva versus standard therapy including British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) response at week 52, sustained corticosteroid control from week 40 to 52, sustained SRI-4 from week 40 to 52, a six-point improvement in SLE disease activity score (SRI-6) at 52 weeks, and time to first flare over 52 weeks as defined by the British Isles Lupus Assessment Group (BILAG) index.

SLE affects over three million people worldwide, mostly women diagnosed between the ages of 15 and 45, with women of color disproportionately impacted. Frequent flares of disease activity inflame and damage multiple organs. Around half of the patients will progress to lupus nephritis, a potentially life-threatening kidney complication, within five years of diagnosis. Achieving better disease control can reduce flares, limit further damage to the organs and lower the risk of developing lupus nephritis.

Data will be presented at an upcoming medical meeting and shared with health authorities as soon as possible, including the U.S. Food and Drug Administration and the European Medicines Agency. If approved, Gazyva would be the first anti-CD20 therapy for SLE to directly target B cells, an underlying cause of disease.

ALLEGORY is the third positive Phase III study for Gazyva in immune-mediated diseases, in addition to REGENCY in lupus nephritis and INShore in idiopathic nephrotic syndrome. This growing evidence suggests that Gazyva, designed to attack and destroy targeted B cells, both directly and together with the body's immune system, may help address disease activity across a spectrum of autoimmune or immune-related diseases.

In addition to SLE, Gazyva is being investigated in children and adolescents with lupus nephritis, as well as adults with membranous nephropathy, as part of our ambition to be leaders in immune-mediated rheumatology and nephrology diseases.

About Gazyva

Gazyva® (obinutuzumab) is a humanized monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells. Gazyva is approved for adults with lupus nephritis in the U.S. who are receiving standard therapy. In October 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval in the European Union, with a final decision expected from the European Commission in the near future. Gazyva is also approved in 100 countries for various types of hematological cancers.

About the ALLEGORY Study

ALLEGORY [NCT04963296] is a Phase III, randomized, double-blind, placebo-controlled, multicenter study, investigating the efficacy and safety of Gazyva® (obinutuzumab) compared with standard therapy in adults with systemic lupus erythematosus (SLE) on standard therapy. The study enrolled approximately 300 people, who were randomized 1:1 to receive Gazyva or placebo for up to one year (52 weeks), followed by an open-label period with Gazyva for up to 104 weeks. The primary endpoint is the percentage of people who achieve SLE Responder Index four at week 52.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease that affects more than three million people worldwide, and rising. Due to the non-specific symptoms, it can take two to six years for an accurate diagnosis. During this time, disease severity and organ damage, due to repeated flares of disease activity, typically worsens and quality of life declines.

Around half of people with SLE will develop lupus nephritis within five years of a lupus diagnosis. In lupus nephritis, the disease activity primarily affects the kidneys and there is a risk of end-stage kidney disease, where dialysis and transplant are the only treatment options.

There is a need for additional targeted therapies that can effectively control disease activity and potentially delay or prevent the onset of lupus nephritis.

GAZYVA Indications

GAZYVA® (obinutuzumab) is a prescription medicine used:

With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment

With the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment

With chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III, or IV FL in adults who have not had previous FL treatment

for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy

Important Safety Information

The most important safety information patients should know about GAZYVA

Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that can become serious or life-threatening, including:

Hepatitis B Virus (HBV): Hepatitis B can cause liver failure and death. If the patient has a history of hepatitis B infection, GAZYVA could cause it to return. Patients should not receive GAZYVA if they have active hepatitis B liver disease. The patient’s doctor or healthcare team will need to screen them for hepatitis B before, and monitor the patient for hepatitis during and after, their treatment with GAZYVA. Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin or eyes

Progressive Multifocal Leukoencephalopathy (PML): PML is a rare and serious brain infection caused by a virus. PML can be fatal. The patient’s weakened immune system could put them at risk. The patient’s doctor will watch for symptoms. Symptoms of PML include: confusion, difficulty talking or walking, dizziness or loss of balance, and vision problems

Who should not receive GAZYVA:

Patients should NOT receive GAZYVA if they have had an allergic reaction (e.g., anaphylaxis or serum sickness) to GAZYVA. Patients must tell their healthcare provider if they have had an allergic reaction to obinutuzumab or any other ingredients in GAZYVA in the past.

Additional possible serious side effects of GAZYVA:

Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that may become severe or life-threatening, including:

Infusion-Related Reactions: These side effects may occur during or within 24 hours of any GAZYVA infusion. Some infusion-related reactions can be serious, including, but not limited to, severe allergic reactions (anaphylaxis), acute life-threatening breathing problems, or other life-threatening infusion-related reactions. If the patient has a reaction, the infusion is either slowed or stopped until their symptoms are resolved. Most patients are able to complete infusions and receive medication again. However, if the infusion-related reaction is life-threatening, the infusion of GAZYVA will be permanently stopped. The patient’s healthcare team will take steps to help lessen any side effects the patient may have to the infusion process. The patient may be given medicines to take before each GAZYVA treatment. Symptoms of infusion-related reactions may include: fast heartbeat, tiredness, dizziness, headache, redness of the face, nausea, chills, fever, vomiting, diarrhea, rash, high blood pressure, low blood pressure, difficulty breathing, and chest discomfort

Hypersensitivity Reactions Including Serum Sickness: Some patients receiving GAZYVA may have severe or life-threatening allergic reactions. This reaction may be severe, may happen during or after an infusion, and may affect many areas of the body. If an allergic reaction occurs, the patient’s doctor will stop the infusion and permanently discontinue GAZYVA

Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving GAZYVA. GAZYVA works to break down cancer cells quickly. As cancer cells break apart, their contents are released into the blood. These contents may cause damage to organs and the heart and may lead to kidney failure requiring the need for dialysis treatment. The patient’s doctor may prescribe medication to help prevent TLS. The patient’s doctor will also conduct regular blood tests to check for TLS. Symptoms of TLS may include nausea, vomiting, diarrhea, and tiredness. TLS is not identified as a risk in LN

Serious, Including Fatal, Infections: While the patient is taking GAZYVA, they may develop infections. Some of these infections may be fatal and severe, so the patient should be sure to talk to their doctor if they think they have an infection. Patients administered GAZYVA in combination with chemotherapy, followed by GAZYVA alone are at a high risk of infections during and after treatment. Patients with a history of recurring or chronic infections may be at an increased risk of infection. Patients taking GAZYVA plus standard therapy may be at higher risk for fatal or severe infections compared to patients taking standard therapy plus placebo. Patients with an active infection should not be treated with GAZYVA. Patients taking GAZYVA plus bendamustine may be at higher risk for fatal or severe infections compared to patients taking GAZYVA plus CHOP or CVP. If the patient develops a serious infection, your doctor will immediately discontinue GAZYVA and begin treatment for the infection.

Low White Blood Cell Count: When the patient has an abnormally low count of infection-fighting white blood cells, it is called neutropenia. While the patient is taking GAZYVA, their doctor will do blood work to check their white blood cell count. Severe and life-threatening neutropenia can develop during or after treatment with GAZYVA. Some cases of neutropenia can last for more than one month. If the patient’s white blood cell count is low, their doctor may prescribe medication to help prevent infections

Low Platelet Count: Platelets help stop bleeding or blood loss. GAZYVA may reduce the number of platelets the patient has in their blood; having low platelet count is called thrombocytopenia. This may affect the clotting process. While the patient is taking GAZYVA, their doctor will do blood work to check their platelet count. Severe and life-threatening thrombocytopenia can develop during treatment with GAZYVA. Fatal bleeding events have occurred in patients treated with GAZYVA. If the patient’s platelet count gets too low, their treatment may be delayed or reduced

Disseminated Intravascular Coagulation (DIC): Fatal and severe DIC has been reported in people receiving GAZYVA. DIC is a rare and serious abnormal blood clotting condition that should be monitored and managed by the patient’s doctor as it can lead to uncontrollable bleeding

The most common side effects of GAZYVA in CLL were infusion-related reactions and low white blood cell counts.

The most common side effects seen with GAZYVA in a study that included relapsed or refractory NHL, including FL patients were infusion-related reactions, fatigue, low white blood cell counts, cough, upper respiratory tract infection, and joint or muscle pain.

The most common side effects seen with GAZYVA in a study that included previously untreated FL patients were infusion-related reactions, low white blood cell count, upper respiratory tract infections, cough, constipation and diarrhea.

The most common side effects of GAZYVA in LN were upper respiratory tract infection, COVID-19, urinary tract infection, bronchitis, pneumonia, infusion infusion-related reactions, and neutropenia.

Before receiving GAZYVA, patients should talk to their doctor about:

Immunizations: Before receiving GAZYVA therapy, the patient should tell their healthcare provider if they have recently received or are scheduled to receive a vaccine. Patients who are treated with GAZYVA should not receive live vaccines

Pregnancy: The patient should tell their doctor if they are pregnant, think that they might be pregnant, plan to become pregnant, or are breastfeeding. GAZYVA may harm their unborn baby. The patient should speak to their doctor about using GAZYVA while they are pregnant. The patient should talk to their doctor or their child’s doctor about the safety and timing of live virus vaccinations to their infant if they received GAZYVA during pregnancy. Women of childbearing potential should use effective contraception while taking GAZYVA and for 6 months after your GAZYVA treatment

Breastfeeding: Because of the potential risk of serious side reactions in breastfed children, patients should not breastfeed while taking GAZYVA and for 6 months after your last dose

Patients should tell their doctor about any side effects.

These are not all of the possible side effects of GAZYVA. For more information, patients should ask their doctor or pharmacist.

GAZYVA is available by prescription only.

Report side effects to the FDA at (800) FDA-1088, or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.

Please visit https://www.GAZYVA.com for the GAZYVA full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information.

About Genentech in Immunology

Genentech is committed to harnessing pioneering science and innovation to address critical unmet needs for patients with immune-mediated inflammatory diseases. Our pipeline includes over a dozen clinical programs in immunology aiming to transform care for people living with lupus, MASH, ulcerative colitis, Crohn’s disease, immunoglobulin A nephropathy, idiopathic nephrotic syndrome, atopic dermatitis, and rheumatoid arthritis. We are investing end-to-end in immunology from discovery and R&D to commercialization across a variety of modalities including monoclonal antibodies, bispecifics, and CAR-T cell therapies to help solve some of the most difficult challenges in immunology today.

About Genentech

Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1These positive results follow the recent US FDA approval and positive EU CHMP opinion for Gazyva/Gazyvaro in lupus nephritis, alongside positive phase III data from the INShore study in idiopathic nephrotic syndrome Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva/Gazyvaro versus standard therapy.2 SRI is a tool that assesses changes in disease severity, symptoms and physical condition to indicate whether treatment is effective at controlling disease activity. All key secondary endpoints were also met. No new safety signals were identified, and safety was in line with the well-characterised profile of Gazyva/Gazyvaro.

“Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are unprecedented in demonstrating that by effectively controlling disease activity, Gazyva/Gazyvaro may delay or prevent further organ damage in people with SLE,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to sharing the data with global health authorities, with the goal of making this potentially transformative new standard of care available as quickly as possible.”

All key secondary endpoints were met, with results showing statistically significant and clinically meaningful benefits with Gazyva/Gazyvaro versus standard therapy including British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) response at week 52, sustained corticosteroid control from week 40 to 52, sustained SRI-4 from week 40 to 52, a six-point improvement in SLE disease activity score (SRI-6) at 52 weeks, and time to first flare over 52 weeks as defined by the British Isles Lupus Assessment Group (BILAG) index.1

SLE affects over three million people worldwide, mostly women diagnosed between the ages of 15 and 45, with women of colour disproportionately impacted.3-5 Frequent flares of disease activity inflame and damage multiple organs. Around half of the patients will progress to lupus nephritis, a potentially life-threatening kidney complication, within five years of diagnosis.6-8 Achieving better disease control can reduce flares, limit further damage to the organs and lower the risk of developing lupus nephritis.9,10   

Data will be presented at an upcoming medical meeting and shared with health authorities as soon as possible, including the US Food and Drug Administration and the European Medicines Agency. If approved, Gazyva/Gazyvaro would be the first anti-CD20  therapy for SLE to directly target B cells, an underlying cause of disease.2

ALLEGORY is the third positive phase III study for Gazyva/Gazyvaro in immune-mediated diseases, in addition to REGENCY in lupus nephritis and INShore in idiopathic nephrotic syndrome. This growing evidence suggests that Gazyva/Gazyvaro, designed to attack and destroy targeted B cells, both directly and together with the body's immune system, may help address disease activity across a spectrum of autoimmune or immune-related diseases.

In addition to SLE, Gazyva/Gazyvaro is being investigated in children and adolescents with lupus nephritis, as well as adults with membranous nephropathy, as part of our ambition to be leaders in immune-mediated rheumatology and nephrology diseases.

About Gazyva/Gazyvaro
Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death  and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC).11 CD20 is a protein found on certain types of B cells. Gazyva/Gazyvaro is approved for adults with lupus nephritis in the US who are receiving standard therapy. In October 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval in the European Union, with a final decision expected from the European Commission in the near future. Gazyva/Gazyvaro is also approved in 100 countries for various types of haematological cancers.

About the ALLEGORY study
ALLEGORY [NCT04963296] is a phase III, randomised, double-blind, placebo-controlled, multicentre study, investigating the efficacy and safety of Gazyva®/Gazyvaro® (obinutuzumab) compared with standard therapy in adults with systemic lupus erythematosus (SLE) on standard therapy. The study enrolled approximately 300 people, who were randomised 1:1 to receive Gazyva/Gazyvaro or placebo for up to one year (52 weeks), followed by an open-label period with Gazyva/Gazyvaro for up to 104 weeks. The primary endpoint is the percentage of people who achieve SLE Responder Index four at week 52.

About systemic lupus erythematosus   
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease that affects more than three million people worldwide, and rising.3,12 Due to the non-specific symptoms, it can take two to six years for an accurate diagnosis. During this time, disease severity and organ damage, due to repeated flares of disease activity, typically worsens and quality of life declines.9,13,14

Around half of people with SLE will develop lupus nephritis within five years of a lupus diagnosis.7,8 In lupus nephritis, the disease activity primarily affects the kidneys and there is a risk of end-stage kidney disease, where dialysis and transplant are the only treatment options.

There is a need for additional targeted therapies that can effectively control disease activity and potentially delay or prevent the onset of lupus nephritis.15,16

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law. 

References
[1] Yap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci. 2019 Dec 10;20(24):6231.
[2] Clinicaltrials.gov. A study to evaluate the efficacy and safety of obinutuzumab in participants with systemic lupus erythematosus (ALLEGORY). [Internet; cited 2025 October 30]. Available from: https://clinicaltrials.gov/study/NCT04963296.
[3] Tian J, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023 Mar;82(3):351-56.
[4] Bindroo MA, et al. Late Onset Systemic Lupus Erythematosus - Clinical and Autoantibody Profile and its Comparison with Young Onset Systemic Lupus Erythematosus. Mediterr J Rheumatol. 2023 Jul 29;34(4):454–59
[5] Barber MRW, et al. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology (Oxford). 2023 Mar 29;62(Suppl 1):i4-9
[6] Mahajan A, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020 Sep;29(9):1011-20.
[7] Bechler KK, et al. Predicting patients who are likely to develop Lupus Nephritis of those newly diagnosed with Systemic Lupus Erythematosus. AMIA Annu Symp Proc. 2023 Apr 29:2022:221-30.
[8] Anders HJ et al. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7.
[9] Kandane-Rathnayake R, et al. Association of Lupus Low Disease Activity State And Remission With Reduced Organ Damage And Flare in Systemic lupus erythematosus Patients With High Disease Activity. Rheumatology (Oxford). 2025 May 1;64(5):2741-48.
[10] Adamichou C, et al. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017 Mar 28;28(1):4-12.
[11] Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42.
[12] Rees F, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-61.
[13] Nightingale AL, et al. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med. 2017 Feb 10;4(1):e000172.
[14] Murimi-Worstell IB, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020 May 21;10(5):e031850.
[15] Hocaoglu M et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network. Arthritis & Rheumatol 2023 Apr;75(4):567-73.
[16] Mok C, et al. Treatment of lupus nephritis: consensus evidence and perspectives. Nat Rev Rheumatol. 2023 Apr;19(4):227-38.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]  

Media Investor Release Gazyva ALLEGORY study English

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida, and online.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) will release earnings results for the third quarter, before the opening bell on Monday, Nov. 3.

Analysts expect the Westbrook, Maine-based company to report quarterly earnings at $3.14 per share, up from $2.80 per share in the year-ago period. The consensus estimate for IDEXX Laboratories' quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier, according to data from Benzinga Pro.

On Aug. 4, IDEXX Laboratories reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates.

Shares of IDEXX Laboratories rose 0.2% to close at $629.51 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Stifel analyst Jonathan Block upgraded the stock from Hold to Buy and raised the price target from $640 to $700 on Oct. 31, 2025. This analyst has an accuracy rate of 72%.
UBS analyst Andrea Alfonso initiated coverage on the stock with a Neutral rating and a price target of $720 on Oct. 1, 2025. This analyst has an accuracy rate of 78%.
Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 on Aug. 15, 2025. This analyst has an accuracy rate of 73%.
Piper Sandler analyst David Westenberg maintained a Neutral rating and increased the price target from $510 to $700 on Aug. 11, 2025. This analyst has an accuracy rate of 73%.
JP Morgan analyst Chris Scott maintained an Overweight rating and raised the price target from $550 to $675 on Aug. 4, 2025. This analyst has an accuracy rate of 62%
Considering buying IDXX stock? Here’s what analysts think:

Read This Next:

Wall Street’s Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 6% Dividend Yields
Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of LOCO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

Samsung Epis Holdings to be listed on Korea Exchange (KRX) on November 24, 2025Samsung Epis Holdings to focus on exploring next-generation growth drivers and optimizing business strategies for its subsidiaries ‒Samsung Bioepis and a new company under Samsung Epis HoldingsSamsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings while the new subsidiary company under Samsung Epis Holdings will focus on developing next-generation biotechnology platforms
INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings.

The new investment holding company will focus on discovering and securing investment opportunities in biotechnology for the company and its subsidiaries’ long-term growth, with scientific innovation remaining the source of our value creation.

Share
Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis. "The new investment holding company will focus on discovering and securing investment opportunities in biotechnology for the company and its subsidiaries’ long-term growth, with scientific innovation remaining the source of our value creation. In the meantime, Samsung Bioepis will remain committed to ensuring the continued development, manufacturing, and distribution of quality-assured biosimilar medicines to patients around the world,” said Kyung-Ah Kim, President and CEO of Samsung Epis Holdings. “By establishing an independent decision-making structure, we see the potential for further growth and investment. Progress is being made to secure next-generation therapeutic technology on the back of the capabilities accumulated through our biosimilar business. With the spin-off, we expect to have more opportunities to explore next-generation growth drivers.”

Samsung Epis Holdings Co., Ltd.

As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings will optimize business strategies for its subsidiaries and maximize corporate and shareholder value through proactive R&D and investment. Samsung Epis Holdings will implement and deploy a focused growth strategy designed to ensure efficient and effective resources while reinforcing the business strategies and platforms for the two subsidiaries.

The New Subsidiary Company

The new subsidiary company under Samsung Epis Holdings will develop next-generation biotechnology platforms targeting various modalities to identify future growth engines beyond the biosimilar business and drive innovation. The new subsidiary will focus on transforming highly scalable core technologies into platforms and discovering diverse new drug candidates, including joint development with global pharmaceutical companies.

For more information about Samsung Epis Holdings and its new subsidiary, please visit: https://www.samsungepisholdings.com/en/

Samsung Bioepis Co., Ltd.

Samsung Bioepis will continue to focus on its core business, including research and development, manufacturing, supply distribution, and commercialization of biologic medicines. Since its foundation in 2012, Samsung Bioepis has developed the industry’s most rapidly advancing biosimilar medicines portfolio, with 11 biosimilars approved and available around the world. In 2024, the company achieved record-breaking sales of KRW 1.5377 trillion and operating profit of KRW 435.4 billion. Samsung Bioepis will focus on strengthening its development capabilities, with a goal of securing 20+ biosimilars in the long-term. Samsung Bioepis has already opened up access to biologic medicines across immunology, oncology, ophthalmology, hematology, and nephrology, and the company is expanding into other therapeutic areas to address unmet needs of patients. For more information about Samsung Bioepis, please visit: www.samsungbioepis.com and follow Samsung Bioepis on social media – LinkedIn, X.

More News From Samsung Epis Holdings Co., Ltd.

Back to Newsroom

SummaryFour new preferred stock and baby bond offerings were tracked, with yields ranging from 6.25% to 7.375%, including DTK, XELLL, TCPA, and CCID.DTK (DTE Energy) and XELLL (Xcel Energy) both achieved a perfect Compliance Score, offering 6.25% fixed coupons and investment-grade ratings.Current high-quality preferreds and ETDs (Compliance Score 10) are trading at a 2% discount to par, with an average yield of 6.62%.Investors can often buy new preferred shares at wholesale prices via OTC markets, and tracking par crosses helps identify bargains in the sector. Richard Drury/DigitalVision via Getty Images

New Offering Summaries: Of the various offerings we will summarize below, two of them, DTK and XELLL (both energy companies and both offering junior subordinated notes due 2085), achieved a perfect “Compliance Score” on our ten-point scale. Long-time readers of our

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"), of the important November 7, 2025 lead plaintiff deadline.

So what: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Savara class action, go to https://rosenlegal.com/submit-form/?case_id=44874 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete submission of the MOLBREEVI BLA within the timeframe that Savara had represented to investors; (4) the delay in MOLBREEVI's regulatory approval increased the likelihood that Savara would need to raise additional capital; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Savara class action, go to https://rosenlegal.com/submit-form/?case_id=44874 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.